Departmental Hosptital of Vendee Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT02609828
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre hospitalier departemental Vendée | Departmental Hospital Center of Vendee | Departmental Hospital Centre - Vendee | EPSM de Vendée Georges Mazurelle

Active Ingredients

Drugs in Phase 3 Trials (1)

tanezumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cancer Pain (Phase 3)

Musculoskeletal Pain (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1